This bill amends various sections of Florida law concerning the Department of Health, with a primary focus on the regulation of medical marijuana and the establishment of a new grant program for neurofibromatosis research. Key changes include a revised definition of low-THC cannabis, updated requirements for the approval of qualified physicians and medical directors at medical marijuana treatment centers, and a prohibition on these centers being located within 500 feet of parks, child care facilities, and schools. However, counties and municipalities are granted the authority to approve the location of dispensing facilities within these distances under certain conditions, and facilities approved before a specified date are exempt from these restrictions.

Additionally, the bill creates the Neurofibromatosis Disease Grant Program to support research and development of treatments for neurofibromatosis through competitive grants awarded based on a peer-reviewed process. It establishes a research institute dedicated to advancing treatments for neurofibromatosis, ensuring equal access for all qualified investigators to compete for funding, and promoting collaboration among institutions. The bill also includes provisions for educational materials on the nutritional needs of preterm infants, updates to the Early Steps Program, and changes to licensure requirements for health care practitioners. Other amendments include the creation of a micro-credential for autism support training at the University of Florida and modifications to the delegation of duties for registered nurses regarding controlled substances. The bill is set to take effect on July 1, 2026.

Statutes affected:
S 902 Filed: 391.3081, 1004.551
S 902 c1: 391.3081, 464.0156, 1004.551
S 902 c2: 391.3081, 464.0156, 491.005, 1004.551
S 902 c3: 391.3081, 464.0156, 491.005, 1004.551